ID: h-e7e1f943
Hypothesis
Microbial Inflammasome Priming Prevention
Pathogenic gut bacteria prime peripheral macrophages through NLRP3 inflammasome activation, creating a systemic pro-inflammatory state that enhances neuroinflammation and dopaminergic neuron vulnerability.
EvidencePending (0%)📖 47 cit🗣 2 debates✓ 5 support✗ 3 oppose
✓ All Quality Gates Passed
🧪 Overview
Pathogenic gut bacteria prime peripheral macrophages through NLRP3 inflammasome activation, creating a systemic pro-inflammatory state that enhances neuroinflammation and dopaminergic neuron vulnerability. Selective inflammasome inhibitors combined with microbiome restoration could break this inflammatory cycle.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Microbial PAMPs<br/>LPS and Bacterial Components"] --> B["TLR4 and PRR<br/>Pattern Recognition"]
B -->|"Signal 1"| C["NF-kappaB Nuclear<br/>Translocation"]
C --> D["Pro-IL1B and Pro-IL18<br/>Transcription"]
E["ATP and Danger Signals<br/>Extracellular"] -->|"Signal 2"| F["P2X7 Receptor<br/>Activation"]
F --> G["Potassium Efflux<br/>and ROS Generation"]
G --> H["NLRP3 Protein<br/>Conformational Change"]
D --> I["Cytoplasmic Pro-IL1B<br/>Accumulation"]
H --> J["PYCARD ASC Adapter<br/>Recruitment"]
J --> K["Pro-CASP1<br/>Oligomerization"]
K --> L["Active Caspase-1<br/>Formation"]
I --> L
L -->|"Proteolytic Cleavage"| M["Mature IL1B<br/>Release"]
L --> N["Gasdermin D<br/>Pore Formation"]
M --> O["Neuroinflammatory<br/>Cascade Activation"]
N --> P["Pyroptotic Cell Death<br/>and DAMP Release"]
P --> Q["Microglial Activation<br/>and Proliferation"]
Q --> R["Synaptic Dysfunction<br/>and Neurodegeneration"]
S["NLRP3 Inhibitors<br/>MCC950 Treatment"] -->|"Therapeutic Block"| H
T["Caspase-1 Inhibitors<br/>VX-765 Compounds"] --> L
U["IL1B Antagonists<br/>Anakinra Therapy"] --> O
O --> R
classDef normal fill:#4fc3f7,stroke:#2196f3,color:#0d0d1a
classDef therapeutic fill:#81c784,stroke:#4caf50,color:#0d0d1a
classDef pathology fill:#ef5350,stroke:#f44336,color:#0d0d1a
classDef outcome fill:#ffd54f,stroke:#ff9800,color:#0d0d1a
classDef molecular fill:#ce93d8,stroke:#9c27b0,color:#0d0d1a
class A,B,E,F normal
class H,J,K,L,I,M,N molecular
class O,Q,P pathology
class R outcome
class S,T,U therapeutic
class C,D,G normal⚖️ Evidence
⚖️ Evidence Matrix5 supports3 contradicts
Supports
NLRP3 inflammasome in neuroinflammation and central nervous system diseases.
Supports
Microglial CMPK2 promotes neuroinflammation and brain injury after ischemic stroke.
Supports
NAD(+) supplementation reduces neuroinflammation and cell senescence in a transgenic mouse model of Alzheimer's disease via cGAS-STING.
Supports
Berberine ameliorates depression-like behaviors in mice via inhibiting NLRP3 inflammasome-mediated neuroinflammation and preventing neuroplasticity disruption.
Supports
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Contradicts
MCC950/NLRP3 inhibition has strong preclinical rationale but translational pharmacology and safety limitations remain unresolved for chronic neurodegenerative use.
Contradicts
A Parkinson NLRP3 inhibitor study focused on anti-inflammatory biomarker effects rather than demonstrated disease modification, leaving the clinical impact of inflammasome blockade uncertain.
Contradicts
Gut-inflammasome links are framed as axis-level physiology and pathology, but do not prove that bacterial inflammasome priming is the dominant driver of dopaminergic vulnerability.
📖 Linked Papers (30)Export BibTeX ↗
The Immuno-Glial Connectome in Alzheimer's Disease: Integrating Central and Peripheral Inflammatory Networks.
Cellular and molecular neurobiology (2026) · PubMed:41569436 ↗
6 figures

Fig. 1
Dynamic microglial activation programs and signaling networks in Alzheimer’s disease (AD). Under physiological conditions, microglia exist in a state of homeost...

Fig. 2
Schematic representation of astrocytic activation and neuroinflammatory pathways in Alzheimer’s disease (AD). Exposure to amyloid-β (Aβ) or injury triggers reac...
Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease.
Autophagy (2020) · PubMed:30966861 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Access to Kidney Transplantation after a Failed First Kidney Transplant and Associations with Patient and Allograft Survival: An Analysis of National Data to Inform Allocation Policy.
Clinical journal of the American Society of Nephrology : CJASN (2019) · PubMed:31337621 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Bacterial Density and Biofilm Structure Determined by Optical Coherence Tomography.
Scientific reports (2019) · PubMed:31278369 ↗
9 figures

Figure 1
2D cross-sectional OCT images of the four case biofilms evaluated. The scale bars indicate 100 µm.

Figure 2
Influence of the OCT focus point on the signal intensity distribution across a 2D cross-sectional image of a homogeneous agar layer. OCT images represent the cr...
Electrical transportation mechanisms of molybdenum disulfide flakes-graphene quantum dots heterostructure embedded in polyvinylidene fluoride polymer.
Scientific reports (2019) · PubMed:31043694 ↗
5 figures

Figure 1
( a ) TEM image of the MoS 2 flake decorated with GQDs. ( b ) TEM image of the GQDs on the MoS 2 . ( c ) HR-TEM image of the GQDs on the few-layer MoS 2 . ( d ...

Figure 2
Schematic diagram of the sandwiched MIM device. ( a ) Reference device and ( b ) tristable switching device. ( c ) SEM cross-sectional structure characterizatio...
Interweaving microglial senescence and gut microbiome dynamics in Alzheimer's disease - Mechanisms and therapeutic frontiers.
Molecular and cellular neurosciences (2026) · PubMed:41747877 ↗
No figures
Elevated expression of the NLRP3 inflammasome in post-mortem brain white matter and immune cells in multiple sclerosis.
Multiple sclerosis and related disorders (2026) · PubMed:41687275 ↗
No figures
NLRP3 Inflammasome and Polycystic Ovary Syndrome (PCOS): A Novel Profile in Adipose Tissue.
International journal of molecular sciences (2026) · PubMed:41596350 ↗
No figures
Molecular links between inflammatory bowel disease and Alzheimer's disease through immune signaling and inflammatory pathways.
World journal of gastroenterology (2025) · PubMed:41480321 ↗
No figures
Sepsis and the Liver.
Diseases (Basel, Switzerland) (2025) · PubMed:41439929 ↗
No figures
Systemic inflammation as a central player in the initiation and development of Alzheimer's disease.
Immunity & ageing : I & A (2025) · PubMed:40841660 ↗
No figures
Bone marrow vacuolization to curative strategies: Evolving paradigms in VEXAS syndrome management.
Current research in translational medicine (2025) · PubMed:40784090 ↗
No figures
📙 Related Wiki Pages (15)
Neurofilament Light Chain (NfL) - BiomarbiomarkerNeurofilament Light Chain (NfL) in BloodbiomarkerNfL-Guided Neuroprotection ThresholdideaNES ProteinproteinNLRP3 (NLR Family Pyrin Domain ContaininproteinPYCARD/ASC ProteinproteinIL1B — Interleukin-1 BetaproteinCASP1 GenegenePYCARD GenegeneIL1B Gene - Interleukin 1 BetageneGlutamate - Excitotoxicity and NeurodegebiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerExosomal miR-155 in NeurodegenerationbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerMetabolomic Biomarkers in Neurodegeneratbiomarker
🏥 Translation
🧬 3D Protein Structure — NLRP3
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NLRP3, CASP1, IL1B, PYCARD from GTEx v10.
💉 Clinical Trials (3)Relevance: 4%
0
Active
Active
0
Completed
Completed
0
Total Enrolled
Total Enrolled
Clinical trial NCT03808389Unknown
Unknown·NCT03808389
Clinical trial NCT03671785Unknown
Unknown·NCT03671785
Clinical trial NCT02269150Unknown
Unknown·NCT02269150
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NLRP3, CASP1, IL1B, PYCARD.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
18 months
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
7d Trend
↘
Falling
7d Momentum
▼ 2.9%
Volatility
High
0.0573
Events (7d)
4
Price History
▼15.9%💾 Resource Usage
LLM Tokens
34,972
$0.2158
Total Cost
$0.2158
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes | be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes | — no observation — | pending | 0.90 |
| If hypothesis is true, intervention leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance | leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance | — no observation — | pending | 0.90 |
🔮 Falsifiable Predictions (2)
pendingconf 90%
If hypothesis is true, intervention leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
Predicted outcome: leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
Falsification: Intervention fails to leverage liposomal encapsulation and targeted nanoparticle technologies to enhance compound bioavailability and cerebral penetrance
pendingconf 90%
If hypothesis is true, intervention be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
Predicted outcome: be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
Falsification: Intervention fails to be instrumental in comprehensively understanding the complex interactions underlying neuroinflammatory processes
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.